Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets tough head and neck cancers in Mid-Stage trial

NCT ID NCT06857279

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Mar 06, 2026 · Last updated May 12, 2026 · Updated 11 times

Summary

This study tests an experimental drug called HLX43 in people whose head and neck cancer has returned or spread to other parts of the body. The drug works by attaching a cancer-killing agent to an antibody that targets a protein (PD-L1) on tumor cells. About 167 adults aged 18 to 75 will receive the drug to see if it shrinks tumors and how safe it is. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA OF HEAD AND/OR NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

    RECRUITING

    Jinan, Shandong, 250117, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CARCINOMA OF HEAD AND/OR NECK